Vinpocetine Covex 5 mg improves cerebral blood flow, decreases cerebral vascular oxygen and glucose utilization. Vinpocetine Covex 5 mg inhibits phosphodiesterase activity, prevent platelet aggregation and adenosine intake by erythrocytes.
It diminishes or suppresses disturbances due to hypoxia or deficient cerebral metabolism.
The finished dosage form of Vinpocetine (Vinpocetine Covex 5 mg) is marketed as a prescription product in Azerbaijan, Armenia, Belarus, Bulgaria, Cuba, Georgia, Hungary, Kazakhstan, Latvia, Lithuania, Mongolia, Portugal, Czech Republic, Slovakia, Spain, Russia, Ukraine.
IMPORTANT INFORMATION ON COOKIES:
You may restrict, block or delete cookies from COVEX, S.A. Or any other web page, using your browser. In each browser the operation is different (the 'Help' function will show you how to do it.) Here we show the links where you can see how to configure blocking of the most common browsers:
Authorized Personnel Only
By accessing this website you accept and agree to the Data Protection and Legal Information. In order to comply with Spanish legislation on Advertising of Medicinal Products for Human Use, we must inform you that the information below is intended for health professionals.
If you are not a healthcare professional, please refrain from accessing this website.Access, I am a healthcare professional No access, I am a not healthcare professional